NecroX-5 exerts anti-inflammatory and anti-fibrotic effects via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway in hypoxia/reoxygenation-treated rat hearts

Vu Thi Thu1,2, Hyoung Kyu Kim1,2, Le Thanh Long1, To Thanh Thuy3, Nguyen Quang Huy1, Soon Ha Kim4, Nari Kim1, Kyung Soo Ko1, Byoung Doo Rhee1, and Jin Han1,*

1National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea, 2Department of Integrated Biomedical Science, College of Medicine, Inje University, Busan 47392, Korea, 3VNU University of Science, Hanoi 120036, Vietnam, 4Product Strategy and Development, LG Life Sciences Ltd., Seoul 03184, Korea

ARTICLE INFO
Received February 26, 2016
Revised March 4, 2016
Accepted March 4, 2016
*Correspondence Jin Han E-mail: phyhanj@inje.ac.kr

Key Words
Decorin
Hypoxia/reoxygenation
Inflammation
NecroX-5

#These authors contributed equally to this study.

ABSTRACT Inflammatory and fibrotic responses are accelerated during the reperfusion period, and excessive fibrosis and inflammation contribute to cardiac malfunction. NecroX compounds have been shown to protect the liver and heart from ischemia-reperfusion injury. The aim of this study was to further define the role and mechanism of action of NecroX-5 in regulating inflammation and fibrosis responses in a model of hypoxia/reoxygenation (HR). We utilized HR-treated rat hearts and lipopolysaccharide (LPS)-treated H9C2 culture cells in the presence or absence of NecroX-5 (10 μmol/L) treatment as experimental models. Addition of NecroX-5 significantly increased decorin (Dcn) expression levels in HR-treated hearts. In contrast, expression of transforming growth factor beta 1 (TGFβ1) and Smad2 phosphorylation (pSmad2) was strongly attenuated in NecroX-5-treated hearts. In addition, significantly increased production of tumor necrosis factor alpha (TNFα), TGFβ1, and pSmad2, and markedly decreased Dcn expression levels, were observed in LPS-stimulated H9C2 cells. Interestingly, NecroX-5 supplementation effectively attenuated the increased expression levels of TNFα, TGFβ1, and pSmad2, as well as the decreased expression of Dcn. Thus, our data demonstrate potential anti-inflammatory and anti-fibrotic effects of NecroX-5 against cardiac HR injuries via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway.

INTRODUCTION Ischemia-reperfusion (IR) injury is a major contributor to acute myocardial infarction associated with coronary artery disease. Potential mediators of IR are involved in oxidative stress, intracellular and mitochondrial Ca2+ overload, and the accumulation of inflammatory cells in the infarcted myocardial tissue [1-3]. Additionally, inflammatory and fibrotic processes also play major roles in the extension of myocardial infarction. In this context, transforming growth factor beta 1 (TGFβ1) and tumor necrosis factor alpha (TNFα) have been implicated as important factors that are responsible for triggering and mediating these inflammatory and fibrotic responses [4-7]. In response to acute myocardial infarction, TNFα is released from macrophages, monocytes, and mast cells to trigger the inflammatory response and further contribute to the development of contractile dysfunction. Furthermore, TGFβ1 plays a causal role in myocardial fibrosis and diastolic dysfunction [8]. Inhibition of TGFβ1
production is essential in therapy to reduce cardiac fibrosis [6,8,9]. These two factors may also play a role in the regulation of decorin (Dcn) expression in this context [10-13], as TNFα and TGFβ1 cooperatively or individually downregulate Dcn gene expression to control biological processes [10].

Animal model studies have suggested the beneficial effects of targeting IR with anti-inflammatory and anti-fibrotic treatments [8,14,15], including Dcn pharmacological or gene therapies [14,16,17]. The Dcn molecule is potentially involved in reverse cardiac remodeling via direct inhibition of TGFβ-induced collagen synthesis and anti-fibrotic effects on patients with end-stage heart failure [17]. Dcn expression reportedly increases in myocardial tissue from patients who had undergone implantation of a left ventricular assist device [17]. Also, age-related downregulation of cardiac Dcn gene expression following myocardial IR was described [18]. Following myocardial infarction, cardiac-targeted administration of Dcn may impact TGFβ expression. In the rat heart, Dcn levels begin to increase at 1 week, reach a peak at 2 weeks [19], and remain elevated until 8 weeks following myocardial infarction [20], suggesting that Dcn may sequester latent TGFβ1 and thereby control TGFβ activity [21]. In addition, post-infarction Dcn gene therapy mitigates cardiac remodeling and dysfunction by altering infarct tissue noncardiomyocyte dynamics and preventing cardiac fibrosis in combination with inhibition of Smad2/3 activation [22]. These findings confirm the previously reported anti-fibrotic effect of Dcn in hearts [17]. Moreover, a decrease in myocardial fibrosis is another important manner in which Dcn may suppress both systolic and diastolic dysfunction [23,24].

NecroXs are a series of compounds that have recently been developed by LG Lifescience [25]. NecroX-5 exhibits significant cell and tissue protective potential against various injury factors, including oxidative stress [25], IR injuries [26,27], neomycin [28], nitroprusside [29], and gentamicin [30]. Interestingly, NecroX-7 has been reported to reduce hepatic necrosis and inflammation following IR injury [27]. Recently, we found that post-hypoxic treatment with NecroX-5 reduced oxidative stress and Ca2+ overload in rat heart mitochondria following reoxygenation injury [31] and inhibited sodium nitroprusside-induced cardiac cell death [29]. Furthermore, proteomic analysis revealed that NecroX-5 preserved the cellular level of several anti-inflammatory proteins in hypoxia/reoxygenation (HR)-treated hearts. As an extension of this previous study, we investigated whether NecroX-5 plays a role in modulating inflammatory and fibrotic responses in an ischemic heart. As expected, our data demonstrate that NecroX-5 exerts anti-inflammatory and anti-fibrotic effects against HR injuries via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway.

METHODS

Ethics statement

Our experiments were conducted in accord with the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication No. 85-23, revised 1996). In addition, these experimental protocols were approved by the Institutional Review Board of Animals at the Inje University College of Medicine, and all procedures were performed in agreement with the Institutional Review Board guidelines for the ethical use of animals.

Isolation of hearts

Eight-week-old male Sprague–Dawley rats (weight, 200–250 g each) were anaesthetized with i.p. injection of sodium pentobarbital (100 mg/kg) [32]. The anesthesia was assessed by verification of a lack of nociceptive movement, such as a tail flick reflex. Then, the heart from each animal was quickly mounted and perfused with normal Tyrode’s (NT) solution to remove all blood.

Cardiac perfusion

Hearts were perfused with NT solution for 30 min followed by perfusion with ischemic solution [33] for 30 min. In the HR group, the hearts were then reperfused with NT solution for 60 min. In the NecroX-5 group, NecroX-5 (10 µmol/L in NT solution) was administered to the hearts for 60 min during the reperfusion period. Hearts that were perfused with NT for the entire 120 min were considered the control group.

RNA extraction and real-time PCR

Total RNA was extracted with TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Briefly, frozen tissues (50–100 mg) were ground into powder in liquid nitrogen and then suspended in 1 mL TRIZOL Reagent. Then, RNA was precipitated from the aqueous phase with an equal volume of isopropanol. Following washing in 1 mL 75% ethanol, the RNA pellet was then air-dried and re-dissolved in an appropriate volume of RNase-free water. The RNA was quantified using a spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). Then, the cDNA was synthesized using Taqman RT reagents (Applied Biosystems, Waltham, MA, USA), according to the manufacturer’s recommendations.

The relative mRNA expression of Dcn, TGFβ1, and TNFα were determined in triplicate using SYBR® Premix Ex Taq™ II kit (TaKaRa, Shiga, Japan) with a CFX96 system. This reaction contained cDNA, SYBR green Taq polymerase mixture, and primer pairs (Dcn, forward 5’-caatagcatcaccgtttgg-3’,...
reverse 3' - cccgaagcttctgataaa - 5'; TGFβ1, forward 5' - acgggtcctctccgtctca - 3', reverse 3' - cggccgggtcggtggtt - 5'; and TNFα, forward 5' - ctccagctttatcaagg - 3', reverse 3' - ctcaagaagtagacgctggc - 5'). The mRNA expression levels are presented relative to the determined levels of β-tubulin expression in the corresponding samples.

TNFα production in H9C2 cardiomyoblasts

H9C2 cells were maintained in DMEM with 10% fetal bovine serum. The cells were pretreated for 24 h with NecroX-5 (µmol/L) before stimulation with LPS (10 ng/mL) for 24 h. After this incubation, the cells were detached from the culture dishes with trypsin and then fixed with 80% methanol for 10 min. Cells were then permeabilized with 0.1% PBS-Tween for 20 min. After incubation with 5% BSA in TBS-T to block non-specific protein binding, the cells were incubated with TNFα (Cat. ab9579, Abcam, Cambridge, UK) for 30 min at room temperature. Normal mouse IgG was used as isotype control. Analysis of >10,000 events by flow cytometry (BD Biosciences, Franklin Lakes, NJ, US) was performed [34].

In addition, TNFα production was measured by ELISA using a rat TNF kit (Cat. RAB0480, Sigma, St. Louis, MO, USA) for 2 h at room temperature. Following washing with PBS-T three times, the cells were incubated with the second antibody, Alexa Fluor 488® Abcam, Cambridge, UK) for 30 min at room temperature. Then, the cells were incubated with 5% BSA in TBS-T to block non-specific protein binding, the cells were incubated with the second antibody, Alexa Fluor 488® Abcam, Cambridge, UK) for 30 min at room temperature. Normal mouse IgG was used as isotype control. Analysis of >10,000 events by flow cytometry (BD Biosciences, Franklin Lakes, NJ, US) was performed [34].

TGFβ content release

An ELISA (Cat. ab19558, Abcam) was used to assess the levels of TGFβ1 in H9C2 cell culture supernatants. Cells were plated in tissue culture plates at a density of 3x10⁵ cells/well at 75% confluence and then pretreated with NecroX-5 (10 µmol/L) or vehicle for 24 h. LPS (10 ng/mL) was then added to the culture media, and then cells were incubated for 24 h. The media was then collected and analyzed according to the manufacturer's instructions using a SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA, USA).

Protein extraction for LC-MS and peptide count protein quantification

LC-MS and a non-labeled peptide count protein quantification method were used to analyze the proteomes of rat hearts as described previously [35,36]. Heart proteins were separated via SDS-PAGE on a 12% polyacrylamide gel. Protein bands were sliced from the gels and dehydrated. These proteins were then eluted for tryptic peptide digestion. LC-MS/MS analysis was performed using a ThermoFinnigan ProteomeX workstation LTQ linear ion trap MS equipped with NSI sources (Thermo Electron, San Jose, CA, USA).

Protein annotation and functional network construction

In order to elucidate the molecular functions and biological processes of the identified proteins, the proteins were further categorized and annotated, and functional networks were constructed. Systematic bioinformatics analysis of the proteomes from the HR- and HR+NecroX-5-treated hearts was conducted using STRING 10 (Search Tool for the Retrieval of Interacting Genes/Proteins) [37].

Western blot

Myocardial tissues and H9C2 cells were homogenized in ice-cold RIPA buffer (25 mmol/L Tris·HCl [pH 7.6], 150 mmol/L NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail, and phosphatase inhibitor cocktail). The homogenate sample was sonicated briefly before centrifugation at 13,500 × g for 30 min at 4°C. The BCA assay kit (Pierce, Rockford, IL, USA) was used to quantitate protein. Protein (50–100 µg) was separated by SDS-PAGE on a 10–12% polyacrylamide gel. Proteins were then transferred to nitrocellulose membranes (GE Healthcare, Chalfont St. Giles, UK) and blocked in 5% skim milk for 2 h at room temperature. Membranes were then probed with mouse or rabbit polyclonal antibodies to Dcn, Smad2, or pSmad2 (Abcam), or with mouse monoclonal antibodies to α-tubulin (Sigma-Aldrich) at a 1:500 dilution overnight at 4°C. Following three washes in PBS with Tween 20 (PBS-T, pH 7.4), membranes were incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG secondary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) at a 1:2000 dilution for 2 h at room temperature. Following washing with PBS-T three times, a western blotting detection kit (Abclon Inc., Seoul, Korea) was utilized to visualize the antibody-bound proteins. These experiments were performed in triplicate.

Statistical analysis

Data are presented as means±standard error of the mean (SEM). One-way analysis of variance (ANOVA) was used to assess the differences between the control and the treatment. In addition, a control-to-treatment comparison with respect to time was performed using two-way ANOVA, using Origin 8.0 software (OriginLab, Northampton, MA, USA). p-values of ≤0.05 were considered statistically significant.
RESULTS

Alterations of Dcn expression were assessed using LC-MS and real-time PCR

Protein expression profiling of NecroX-5-treated HR, untreated HR, and control hearts was performed using LC-MS. The Dcn protein expression levels in hearts experiencing HR and NecroX-5-treated hearts are shown in Fig. 1A (red bar). While HR significantly reduced Dcn protein levels, post-hypoxic treatment with NecroX-5 strongly dampened this reduction. Dcn protein levels in control, HR, and NecroX-5-treated hearts were 110.1±14.2%, 68.8±6.3%, and 106.0±4.5%, respectively. Consistent with the proteomic findings, the mRNA expression levels of Dcn were also markedly higher in NecroX-5-treated hearts (77.05±0.72% compared to control) than those in untreated HR hearts (45.91±10.05% compared to control; Fig. 1A, black bar).

Alterations of Dcn and TGFβ1/Smad2 reveal anti-inflammatory and anti-fibrotic properties of NecroX-5

Our previous proteomics study and network analysis [35] revealed a small protein network that comprised three identified proteins (Dcn, collagen alpha-2[I] chain [Col1a2], and lumican [Lum]) and two predicted networking proteins (TGFβ1 and SMAD2; Fig. 1B). These identified proteins function in the modulation of inflammation and fibrosis [10] and interact with TGFβ1 and SMAD2 [17]. Based on this prior network analysis, we further investigated the role of NecroX-5 in Dcn/TGFβ1/Smad2 alterations in HR-treated hearts and LPS-treated myoblasts.

Dcn has been proposed to be a physiological inhibitor of TGFβ1, suggesting that alterations of Dcn may be related to expression of TGFβ1 and the downstream factor Smad2. We examined TGFβ1 expression in order to test whether NecroX-5 attenuates inflammatory and fibrotic processes (Fig. 2). In agreement with our proteomics and real-time PCR results, we observed a significant increase in Dcn protein levels in NecroX-5-treated hearts compared to HR-treated hearts by western blot (1.06±0.01 and 0.69±0.06, respectively; p<0.05; Fig. 2B), while Dcn expression in control hearts was 1.11±0.14 (ratio to control). In addition, we examined the protein expression levels of Smad2 and pSmad2 in total cardiac protein samples. The highest ratio of pSmad2/Smad2 protein was found in HR-treated rat hearts (1.38±0.01, Fig. 2A, 2C). Interestingly, that ratio was decreased in NecroX-5-treated hearts. In control hearts and post-hypoxic treated NecroX-5 hearts, pSmad2/Smad2 ratios were 1.10±0.1 and 1.15±0.01, respectively (Fig. 2A, 2C). Furthermore, mRNA TGFβ1 expression levels were significantly higher in HR-treated hearts and NecroX-5-treated HR hearts (4.31±1.46 and 1.00±0.19, respectively; p<0.05) than in control hearts (0.54±0.05; Fig. 2D); however, these elevated TGFβ1 cytokine levels were markedly attenuated in NecroX-5-treated HR hearts compared to those in the HR-treated hearts.

To further investigate the anti-inflammatory and anti-fibrotic effects of NecroX-5, we measured the levels of TGFβ1, Smad2, and pSmad2 in inflammatory H9C2 cultured cells. As LPS is widely used to stimulate the inflammatory response [34], we pretreated the cultured H9C2 cells with NecroX-5 (10 μmol/L) for 24 h prior to treatment with LPS for 24 h. Inflammation was confirmed by the increased TNFα expression levels in these cells following LPS stimulation (Fig. 3A–C). Supplementation with either NecroX-5 or LPS significantly stimulated TNFα mRNA (Fig. 3A) and protein (Fig. 3B) levels compared to treatment with vehicle alone; however, NecroX-5 treatment effectively suppressed the LPS-stimulated transcription of this cytokine. More specifically, TNFα production was markedly increased to 3.02±0.06 ng/ml (Fig. 3B). Pretreatment with NecroX-5 reduced the observed increases in TNFα production to 1.95±0.05 ng/ml. No significant difference between TNFα levels in the cells treated with NecroX-5 (2.16±0.04 ng/ml), and those receiving control treatment (2.13±0.03 ng/ml) was detected.

Using FACS analysis, we also found that NecroX-5 treatment
NecroX-5 exerts anti-inflammatory and anti-fibrotic effects

Fig. 2. Effect of NecroX-5 on the expression levels of Dcn, Smad, and TGFβ1 in HR-treated cardiac tissue. Immunoblotting was performed for Smad2, pSmad2, Dcn, and α-tubulin (A). Quantitation of the Dcn/α-tubulin ratio (B) and pSmad2/Smad2 ratio (C) are shown. Real-time PCR was performed to assess the mRNA expression of TGFβ1 relative to α-tubulin expression in hearts (D). n=3–4 for each group; *p<0.05 vs. control, †p<0.05 vs. HR.

Fig. 3. Effect of NecroX-5 on the expression level of TNFα, TGFβ1, Dcn, and Smad in LPS-treated H9C2 cells. The mRNA expression levels of TNFα relative to α-tubulin were evaluated by real-time PCR (A), and the TNFα protein concentration in cell lysates was evaluated by ELISA (B). FACS analysis yielded the overlay histogram (left) and graph (right) showing the TNFα levels in LPS-stimulated H9C2 cells with or without supplementation of NecroX-5 (C). The mRNA expression levels of TGFβ1 relative to α-tubulin (D) and TGFβ1 secretion (ng/ml) into the culture media (E) were evaluated by real-time PCR and ELISA assay kit, respectively. Western blot analysis was used to determine the expression of Dcn and α-tubulin (F) and Smad2 and pSmad2 (G). H9C2 cells were pretreated with NecroX-5 (10 μmol/L) for 24 h and then LPS (10 ng/ml) was added for 24 h before harvesting. Flow cytometry involved the acquisition of >10,000 events. n=6 for each group; *p<0.05 vs. control, †p<0.05 vs. LPS.
strongly suppressed TNFα production in LPS-stimulated H9C2 cells (Fig. 3C). As shown in the histogram (Fig. 3C, right panel), TNFα production was highest in the LPS-treated H9C2 cells (3.67±0.86, ratio vs. control), and NecroX-5 supplementation significantly reduced TNFα production to 1.15±0.17 and 0.99±0.15 (ratio vs. control) of the NecroX-5-treatment and the NecroX-5 and LPS co-treated cells, respectively. Moreover, NecroX-5 strongly suppressed the LPS-stimulated transcription of TGFβ1 in H9C2 cells. The supplementation of either NecroX-5 or LPS significantly suppressed the LPS-stimulated transcription of TGFβ1 mRNA expression in comparison to vehicle; however, NecroX-5 effectively suppressed the LPS-stimulated transcription of this cytokine (Fig. 3D). The TGFβ1 mRNA expression level in LPS-stimulated cells was 15.76±4.6 (ratio to α- tubulin), while supplementation by NecroX-5 significantly reduced these levels to 8.81±0.27 (ratio to α-tubulin).

In order to determine whether a decrease in the transcription of TGFβ1 leads to a corresponding reduction in protein secretion, we performed ELISA on media or lysates from H9C2 cell cultures stimulated with the inflammatory protocols described above. As expected, the released TGFβ1 concentrations were significantly diminished in samples treated with NecroX-5 and LPS compared to those treated with LPS alone (Fig. 3E). After 24 h of LPS stimulation, TGFβ1 protein levels in control, LPS, NecroX-5, and NecroX-5 plus LPS cultures were 0.073±0.007, 0.112±0.023, 0.076±0.008, and 0.068±0.009 ng/ml, respectively (Fig. 3E); however, no significant difference between the NecroX-5-treated cells and the LPS and NecroX-5 co-treated cells was detected. Overall, these data demonstrate that treatment of LPS-stimulated H9C2 cells with NecroX-5 strongly suppresses TGFβ1 production.

Furthermore, following LPS stimulation, levels of Dcn, Smad2, and pSmad2 in H9C2 cells were also examined by western blotting analysis (Fig. 3F, 3G). LPS treatment significantly reduced Dcn protein levels in H9C2 cells (Fig. 3F). The ratio of Dcn expression to α-tubulin expression in LPS-stimulated H9C2 cells was 0.48±0.14, while in the control group, this value was 0.94±0.03 (ratio to control). NecroX-5 treatment did not increase Dcn protein level compared to control; however such treatment attenuated the LPS-induced reduction in Dcn expression (0.69±0.07, ratio to control). In addition, LPS treatment significantly increased phosphorylation of Smad2 (pSmad2/Smad2 ratio), a downstream target of TGFβ1 in the cellular inflammation response (1.33±0.12, ratio to control; Fig. 3G). This increase was strongly attenuated in cells treated with NecroX-5 (1.05±0.01, ratio to control), although NecroX-5 treatment did not affect the phosphorylation level of Smad2 (0.99±0.01, ratio to control). Collectively, these data suggest that in the presence of pro-inflammatory stimulation, NecroX-5 suppresses the activation of TNFα, an upstream inhibitory regulator of Dcn, which further suppresses TGFβ1/Smad2-mediated inflammation.

**DISCUSSION**

In this study, we described the novel action of NecroX-5 as an anti-inflammatory or anti-fibrotic agent in acute HR injury or chronic inflammation via modulation of the TNFα/Dcn/TGFβ1/Smad2 signaling pathway (summarized in Fig. 4). Fibrosis and inflammation are major pathological responses and represent a hallmark of cardiac remodeling associated with impaired contractility and reduced cardiac function [17,38,39]. To date, multiple experimental studies demonstrated a dramatic reduction in cardiac malfunction following use of specific anti-inflammatory and anti-fibrosis strategies, such as modulation of TNFα and TGFβ expression [14,40]. Importantly, both TNFα and TGFβ also potentially contribute to the regulation of Dcn expression [10-13].

Given the fact that TGFβ plays an important role during healing after myocardial infarction by inducing fibroblast proliferation, increasing extracellular matrix protein synthesis, driving scar formation, and subsequently affecting cardiac remodeling and function [9,22,41,42], considerable attention has focused on development of new compounds to suppress TGFβ activity [8]. Accordingly, blockade of the TGFβ/Smad pathway reduced fibrosis and improved cardiac function [8,43]. Among the most recent successful interventions, Dcn has been suggested...
to be a physiological inhibitor of TGFβ and to limit the duration of the TGFβ response during inflammation, fibrosis, and tissue repair [17,44]. The ability of Dcn to prevent tissue fibrosis and promote tissue regeneration has been described for various injury models [16,17,44-46]. Dcn has been reported to function in reverse cardiac remodeling via direct inhibition of TGFβ-induced collagen synthesis [17]. The function and tissue expression of Dcn has led to the suggestion that this factor plays a protective role following myocardial infarction [18,47]. In rat hearts, Dcn levels begin to increase and remain elevated for weeks, suggesting that Dcn may sequester latent TGFβ1 and thereby exert beneficial control over TGFβ activity [19-21]. In addition, recent evidence from recombinant adeno-associated viral-mediated Dcn overexpression suggests that Dcn exerts potential anti-fibrotic effects to inhibit cardiac fibrosis [48]. In agreement with a previous report [17], post-infarction Dcn gene mitigates the adverse effects on left ventricular geometry and function by affecting cardiac fibrosis and infarct tissue dynamics through the TGFβ1/Smad2/Smad3 pathway. Myocardial fibrosis contributes to both systolic and diastolic dysfunction [23,24], and thus, reduction of this fibrosis is likely another important way that Dcn may modulate left ventricular remodeling and improve cardiac function. Moreover, Dcn gene therapy also significantly increases proliferation of both cardiac myofibroblasts and vascular endothelial cells, suggesting this gene modulation preserves the infarct wall thickness, reduces wall stress, and mitigates left ventricular dilatation and dysfunction [22]. Exercise has a various benefit for the cardiac protection by itself or combined with other medicines [49,50]. Interestingly, chronic exercise is another stimulating factor of Dcn expression and release from skeletal muscle [17]. These findings could suggest the Dcn can be a mediator of exercise-induced anti-inflammatory or anti-fibrosis response.

In our study, NecroX-5 treatment induced markedly higher Dcn expression levels than those observed in untreated hearts (Fig. 2). We found that this increase in Dcn was associated with a concomitant decrease in TGFβ1 expression. Thus, the roles of NecroX-5 on the downregulation of TGFβ1 via Dcn may be explained by two possibilities. Firstly, NecroX-5 may inhibit transcription and translation of TGFβ1, subsequently eliminating the inhibitory effect of this cytokine on the Dcn gene expression (i.e., a downregulated regulator of Dcn). Secondly, lower TGFβ1 in NecroX-5-treated hearts may result from direct binding of Dcn to TGFβ1 with high affinity [51]. Consistent with a previous report [52], increased Dcn production may indicate a mechanism by which cells counteract an injury induced via high glucose-stimulated TGFβ1. This signaling pathway was also reported by Kahari et al. following treatment with dexamethasone [51]. Nevertheless, conflicting data also demonstrate that the modulation of TGFβ1 via Dcn expression is altered in different cell types [10,11,13], leading to questions of whether the Dcn-TGFβ1 complex inactivates or enhances TGFβ activity [53]. Smad2 protein is generally considered a downstream mediator of TGFβ signaling in myocardial inflammation and fibrosis. TGFβ1-stimulated cardiomyocytes exhibit considerable phosphorylated Smad2 (pSmad2) [22,53-55]. In agreement with previous studies [8,43], the lower pSmad2 production observed in NecroX-5-treated samples (Fig. 2, 3) may contribute to a reduction in fibrosis and inflammation, supporting the possibility of cardiac function preservation by NecroX-5. Conversely, earlier studies reported that blockade of the TGFβ1/Smad pathway reduced fibrosis and improved cardiac function [53,54], perhaps via regulation of calcium homeostasis [31]. Thus, downregulation of the TGFβ1/Smad2 pathway by NecroX-5 could potentely improve cardiomyocyte Ca2+ handling and further complement the effect on calcium homeostasis as described in our previous report [6]. Activation of TGFβ1/Smad signaling, however, could reduce or increase cardiac function [56]. Previous studies suggest that Dcn is required for the TGFβ response without changes in the Smad-dependent pathway in myoblasts [12]. Furthermore, increased sequestration of Dcn with TGFβ would also promote cell proliferation [7,34].

Additionally, TNFα is another important mediator of cardiac inflammation [10] and a potent downregulator of Dcn gene expression. In particular, this cytokine exerts its maximal inhibitory effect on promoter sequences relative to the transcription start site of Dcn gene [13]. In our study, TNFα mRNA and protein levels were dramatically increased in LPS-stimulated inflammatory H9C2 cells. Interestingly, these increases were significantly diminished in the presence of NecroX-5 treatment. Consisted with a previous report [10], we found that in inflamed H9C2 cells, TNFα upregulation was accompanied by Dcn downregulation. These alterations led to increased TGFβ1 expression and subsequently resulted in increased Smad2 phosphorylation and elevated inflammation. In this context, TNFα may act independently, as well as exert an additive inhibitory effect with TGFβ1, on Dcn expression. Thus, NecroX-5 administration may beneficially control biological processes via cooperative or specific modulation of TNFα, Dcn, TGFβ1, and Smad2 expression [57,58].

Moreover, inflammation-mediated mitochondrial alterations play a critical role in inflammation-linked diseases [42,59]. Limiting inflammation and consequent mitochondrial function modulation may offer promising therapeutic targets for treatment of ischemic disease. As a result, pharmacological treatments that target mitochondrial pathways may be pursued as a means to treat inflammatory responses [60]. Previously, TNFα was found to modulate inflammation-related mitochondrial function via effects on the mitochondria [60]. These effects included alterations in the mitochondrial complex activity, loss of mitochondrial membrane potential, and decreases in energy production. Mitochondrial Ca2+ and mitochondrial reactive oxygen species, in turn, are primary mediators of TNFα-mediated inflammatory responses [61]. Typically, damaged
mitochondria exhibit reduced bioenergetics, favoring cell damage and death [62,63]. In addition to its interactions with TGFβ and TNFα, Dcn has multiple molecular targets involved in cell growth, and Dcn may also inhibit the production of inflammatory chemokines [64]. Dcn-induced cell cycle arrest via negative modulation of p21 may reduce fibrosis by suppressing proliferation and differentiation of cardiac fibroblasts [31]. In our previous studies, NecroX-5 reduced oxidative stress and preserved mitochondrial function, as evidenced by peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α) expression, mitochondrial complex activity, mitochondrial oxygen consumption, and inner mitochondrial membrane potential (Δψm) against HR injury [35,65]. One possible mechanism of the anti-inflammatory effects of NecroX-5 may be that the anti-oxidant activity successfully prevents hypoxia-induced nuclear factor kappa B (NFκB) and TNFα activation [55]. In addition, our previous study suggested that NecroX-5 removes mitochondrial ROS during LPS-stimulated inflammation, successfully blocking NLRP3 inflammasome activation, as well as NFκB and TNFα activation, in airway epithelial cells [66]. In addition to these findings, the current study suggested that NecroX-5 may regulate the expression of inflammatory factors, including TNFα and TGFβ1/Smad2, in part via modulation of Dcn.

Several limitations of this study need to be mentioned. First, our experiments focused on the effects of Dcn in TNFα/TGFβ1/Smad2-mediated cardiac inflammation and fibrosis in the ex vivo heart during a relatively short period of time (>2 h), and therefore, further studies are required to provide a more comprehensive understanding of the anti-inflammatory and anti-fibrotic roles of NecroX-5 in an in vivo model with long-term monitoring. Second, excessive ROS production during HR treatment may lead to damage and degradation of various proteins; thus, the direct effect of oxidative stress or NecroX-5 on the protein levels of Dcn in HR-treated hearts should be addressed in future studies.

CONCLUSION

Taken together, our data highlight the potential anti-inflammatory and anti-fibrotic effects of NecroX-5 in acute cardiac injury, and these effects may ultimately prevent further pathological remodeling of heart and heart failure.

ACKNOWLEDGMENTS

This work was supported by a grant from the Priority Research Centers Program and Basic Science Research Program through the National Research Foundation of Korea (NRF), Funded by the Ministry of Education, Science and Technology Republic of Korea (2010-0020224, 2012R1A2A1A03007595, and NRF-2015R1D1A1A01057937).

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Halestrap AP. A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans. 2010;38:841-860.
2. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol. 2000;190:255-266.
3. Kleinbongard P, Schulz R, Heusch G. TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev. 2011;16:49-69.
4. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-1553.
5. Schulz R, Aker S, Belosjorow S, Heusch G. TNFα in ischemia/reperfusion injury and heart failure. Basic Res Cardiol. 2004;99:8-11.
6. Bujak M, Frankogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184-195.
7. Mosca S, Gargiulo P, Balato N, Di Costanzo L, Parente A, Paolillo S, Ayala F, Trimarco B, Crea F, Perrone-Filardi P. Ischemic cardiovascular involvement in psoriasis: a systematic review. Int J Cardiol. 2015;178:191-199.
8. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130-135.
9. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-beta1. Mol Genet Metab. 2000;71:418-435.
10. Mauviel A, Santra M, Chen YQ, Uitto J, Iozzo RV. Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-alpha. J Biol Chem. 1995;270:11692-11700.
11. Beanes SR, Dang C, Soo C, Wang Y, Urata M, Ting K, Fonkalsrud EW, Benhaim P, Hedrick MH, Atkinson JB, Lorenz HP. Down-regulation of decorin, a transforming growth factor-beta modulator, is associated with scarless fetal wound healing. J Pediatr Surg. 2001;36:1666-1671.
12. Edwards IJ, Xu H, Wright MJ, Wagner WD. Interleukin-1 up-regulates decorin production by arterial smooth muscle cells. Arterioscler Thromb. 1994;14:1032-1039.
13. Mauviel A, Korang K, Santra M, Tewari D, Uitto J, Iozzo RV. Identification of a bimodal regulatory element encompassing a canonical AP-1 binding site in the proximal promoter region of the human decorin gene. J Biol Chem. 1996;271:24824-24829.
14. Järvinen TA, Ruoslahti E. Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice. Proc Natl Acad Sci U S A. 2010;107:21671-21676.
15. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost. 2009;102:240-247.
NecroX-5 exerts anti-inflammatory and anti-fibrotic effects

16. Mohan RR, Tandon A, Sharma A, Cowden JW, Tovey JC. Significant inhibition of conical scarring in vivo with tissue-selective, targeted AAV5 decorin gene therapy. Invest Ophthalmol Vis Sci. 2011;52:4833-4841.

17. Jahanyar J, Joyce DL, Southard RE, Loebe M, Noon GP, Koerner MM, Torre-Amione G, Youker KA. Decorin-mediated transforming growth factor-beta inhibition ameliorates adverse cardiac remodeling. J Heart Lung Transplant. 2007;26:34-40.

18. Simkhovich BZ, Marjoram P, Poizat C, Kedes L, Kloner RA. Age-related changes of cardiac gene expression following myocardial ischemia/reperfusion. Arch Biochem Biophys. 2003;420:268-278.

19. Hao J, Ju H, Zhao S, Junaid A, Scammell-La Fleur T, Dixon IM. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol. 1999;31:667-678.

20. Weis SM, Zimmerman SD, Shah M, Covell JW, Omens HJ, Ross JR, Dalton N, Jones Y, Reed CC, Iozzo RV, McCulloch AD. A role for decorin in the remodeling of myocardial infarction. Matrix Biol. 2005;24:313-324.

21. Li L, Okada H, Takemura G, Kosai K, Kanamori H, Esaki M, Nakahama N, Takeda K, Komatsubara I, Naito I, Tsuji T. Time-dependent changes of decorin in the infarct zone after experimentally induced myocardial infarction in rats: comparison with biglycan. Pathol Res Pract. 2000;196:23-33.

22. Jiang J, Tu H, Zhao S, Junaid A, Scammell-La Fleur T, Dixon IM. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol. 1999;31:667-678.

23. Weis SM, Zimmerman SD, Shah M, Covell JW, Omens HJ, Ross JR, Dalton N, Jones Y, Reed CC, Iozzo RV, McCulloch AD. A role for decorin in the remodeling of myocardial infarction. Matrix Biol. 2005;24:313-324.

24. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber Jr, Dalton N, Jones Y, Reed CC, Iozzo RV, McCulloch AD. A role for decorin in the remodeling of myocardial infarction. Matrix Biol. 2005;24:313-324.
44. Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR, Pierschbacher MD. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol. 1997;54:1205-1216.

45. Costacurta A, Priante G, D’Angelo A, Chieco-Bianchi L, Cantaro S. Decorin transfection in human mesangial cells downregulates genes playing a role in the progression of fibrosis. J Clin Lab Anal. 2002;16:178-216.

46. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Arch Med Sci. 2011;7:211-216.

47. Yan W, Wang P, Zhao CX, Tang J, Xiao X, Wang DW. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum Gene Ther. 2009;20:1190-1200.

48. Ständer M, Naumann U, Wick W, Weller M. Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res. 1999;296:221-227.

49. Chandel NS, Trzyna WC, McClintock DS, Schumacker PT. Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J Immunol. 2000;165:1013-1021.

50. Russell ST, Eley H, Tisdale MJ. Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell Signal. 2007;19:1797-1806.